Company: CERO
Filing Date: 2025-07-02
Form Type: 424B3
Source: 0001213900-25-061023
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-02
Form: 424B3
Chunk 4
---
           |     | Certificate of Designation of Preferences, Rights and Limitations of the Series D Convertible Preferred Stock, dated April 22, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-40877) filed on April 25, 2025).         |
| 10.1†          |     | Securities Purchase Agreement, dated of April 21, 2025, by and among CERo Therapeutics Holdings, Inc., and the investors signatory thereto (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K (File No. 001-40877) filed on April 22, 2025). |
| 10.2*†         |     | Form of Amendment to the Securities Purchase Agreement.                                                                                                                                                                                                                          |
| 104            |     | Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.                                                                                                                                                                          |

| † | Certain portions of this document that constitute confidential                
 information have been redacted pursuant to Item 601(b)(10) of Regulation S-K. |

| * | Filed herewith. |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: June 30, 2025 | CERO THERAPEUTICS HOLDINGS, INC. 
 By:                              | /s/ Chris Ehrlich       |
|:--------------------|:---------------------------------|:------------------------|
|                     |                                  | Chris Ehrlich           |
|                     |                                  | Chief Executive Officer |

<div align='center'>3</div>